Lifecore Biomedical (LFCR) Q1 2026 earnings summary

Executive summary

• Achieved 26% year-over-year revenue growth in Q3 2025, driven by increased demand, new business wins, and expanded pipeline across new modalities.

• Advanced late-stage pipeline with 11 programs targeting launches between 2026 and 2029, and signed multiple new customer programs.

• Strengthened leadership and culture, implemented operational efficiencies, and completed a favorable FDA audit.

• Operational improvements led to over 20% productivity gains in manufacturing over the past year.

• Expanded customer base with new signings and a major commercial site transfer.

Financial highlights

• Q3 2025 revenue was $31.1 million, up from $24.7 million year-over-year; fiscal 2025 revenues reached $128.9 million, up 0.5%.

• Gross profit rose to $7.8 million from $5.4 million year-over-year.

• Net loss improved to $10 million ($0.29/share) in Q3, and was $38.7 million for fiscal 2025.

• Adjusted EBITDA was $3.1 million in Q3, $19.5 million for fiscal 2025, and projected at $12–$14 million for the transition period.

• SG&A expenses decreased by $5.9 million, reflecting cost control and legacy matter resolution.

Outlook and guidance

• Reaffirmed guidance for May 26–Dec 31, 2025: revenue of $74–$76 million, net loss of $16.4–$18.4 million, and Adjusted EBITDA of $12–$14 million.

• Q4 2025 revenue expected at $34–$36 million, with Adjusted EBITDA of $7–$9 million.

• Targeting 12%+ revenue CAGR and mid-term Adjusted EBITDA margins of 25%+.

• Revenue potential of ~$300 million annually in the mid-term, driven by expanded capacity and pipeline commercialization.

• Expects stronger revenue in the second half of calendar 2026 due to customer order timing.